- Home
- Addressing Vaccine Stability And Cold Chain Challenges With Recombinant Human Serum Albumin To Enable Global Administration
Addressing Vaccine Stability And Cold Chain Challenges With Recombinant Human Serum Albumin To Enable Global Administration
Published on 21 May 2024
Mark Stathos PhD, Product Applications Scientist
Andrew Hamann PhD, Product Applications Scientist
Elliott Renft, Director, Product Applications
CONCLUSIONS
Recombinant human serum albumin (rHSA) was shown to stabilize a variety of virus types both in cold storage over time and across numerous freeze-thaw cycles.
Wiggan et al demonstrated that rice-derived rHSA was shown to be a more potent stabilizer of Dengue Virus than yeast-derived rHSA.
Addressing-Vaccine-Stability-Cold-Chain-Challenges-Recombinant-Human-Serum-Albumin-Enable-Global-Administration Download PDF HereFootnotes
- McCann, N., O’Connor, D., Lambe, T., & Pollard, A. J. (2022). Viral vector vaccines. Current Opinion in Immunology, 77, 102210.
- Blanco-Lobo, P., Nogales, A., Rodríguez, L., & Martínez-Sobrido, L. (2019). Novel approaches for the development of live attenuated influenza vaccines. Viruses, 11(2), 190.
- Sarawar, S., Gabaglia, C. R., Sanchez, A., Hatta, Y., Dias, P., Neumann, G., … & Bilsel, P. (2022). Longevity and Mechanism of Heterosubtypic Protection Induced by M2SR (M2-Deficient Single-Replication) Live Influenza Virus Vaccine in Mice. Vaccines, 10(12), 2131.
- Subbarao, K. (2021). Live attenuated cold-adapted influenza vaccines. Cold Spring Harbor Perspectives in Medicine, 11(9).
- Wiggan O, Livengood JA, Silengo SJ, et al. Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines. Vaccine. 2011;29(43):7456–7462
- Eilts, F., Harsy, Y. M., Lothert, K., Pagallies, F., Amann, R., & Wolff, M. W. (2023). An investigation of excipients for a stable Orf viral vector formulation. Virus Research, 336, 199213.
- Renft, E., & Curl, M. Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin.